How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

13,971 results for

Squamous Cell Carcinoma of the Skin

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

13921. Benign clonal keratinocyte patches with p53 mutations show no genetic link to synchronous squamous cell precancer or cancer in human skin. (PubMed)

Benign clonal keratinocyte patches with p53 mutations show no genetic link to synchronous squamous cell precancer or cancer in human skin. Ultraviolet light, which is the major etiology of human skin cancer, will cause mutations in the p53 gene. We and others have found that such mutations occur in more than one-half of non-melanoma squamous cell cancer and precancer. Immunostaining for p53 has disclosed a characteristic compact pattern not only in cancer/precancer but also in areas (...) of microscopically normal epidermis termed p53 patches. By microdissection, sequence analysis of the p53 gene, and analysis of loss of heterozygosity (LOH) at the site of this gene, we have now extended previous data to ascertain whether these p53 patches are precursors of simultaneously present squamous cell cancer or its morphologically recognized precancerous stages (dysplasia, carcinoma in situ). In none of 11 instances with co-existence of a p53 patch with dysplasia or in situ or invasive cancer were

Full Text available with Trip Pro

1997 The American journal of pathology

13922. Trends for invasive squamous cell neoplasia of the skin in Norway (PubMed)

Trends for invasive squamous cell neoplasia of the skin in Norway Over the period 1966-1995, based on 11,662 patients, the incidence of squamous cell carcinoma of the skin increased three to four times in Norway mainly as a result of an increased number of localized tumours. In men, cancer of the auricle was the second most common site; in women the incidence was low.

Full Text available with Trip Pro

1999 British journal of cancer

13923. Accelerated radiation therapy for locally advanced squamous cell carcinomas of the oral cavity and oropharynx selected according to tumor cell kinetics--a phase II multicenter study. (PubMed)

Accelerated radiation therapy for locally advanced squamous cell carcinomas of the oral cavity and oropharynx selected according to tumor cell kinetics--a phase II multicenter study. A Phase II multicenter trial testing an accelerated regimen of radiotherapy in locally advanced and inoperable cancers of the head and neck, in patients selected on the basis of 5-bromo-2-deoxyuridine/DNA flow cytometry-derived tumor potential doubling time (Tpot).From September 1992 to September 1993, 23 patients (...) consecutively diagnosed to have locally advanced, inoperable carcinomas of the oral cavity and the oropharynx, with Tpot of < or = 5 days, received an accelerated radiotherapy regimen (AF) based on a modification of the concomitant boost technique: 2 Gy/fraction once a day, delivered 5 days a week up to 26 Gy, followed by 2 Gy/fraction twice a day, with a 6-h interval, one of the two fractions being delivered as a concomitant boost to reduced fields, up to 66 Gy total dose (off-cord reduction at 46 Gy

1996 International journal of radiation oncology, biology, physics

13924. Allelic loss at Drosophila patched gene is highly prevalent in Basal and squamous cell carcinomas of the skin. (PubMed)

Allelic loss at Drosophila patched gene is highly prevalent in Basal and squamous cell carcinomas of the skin. The human homolog of the Drosophila Patched gene (PTCH), located at chromosome 9q22.3, is frequently altered in both nevoid basal cell carcinoma syndrome, and sporadic basal cell carcinomas (BCCs). However, alteration of the PTCH gene locus has been poorly studied in squamous cell carcinoma (SCC). We analyzed loss of heterozygosity (LOH) at five markers in and around the PTCH gene

Full Text available with Trip Pro

2006 Journal of Investigative Dermatology

13925. Prolonged prevention of squamous cell carcinoma of the skin by regular sunscreen use. (PubMed)

Prolonged prevention of squamous cell carcinoma of the skin by regular sunscreen use. Half of all cancers in the United States are skin cancers. We have previously shown in a 4.5-year randomized controlled trial in an Australian community that squamous cell carcinomas (SCC) but not basal cell carcinomas (BCC) can be prevented by regular sunscreen application to the head, neck, hands, and forearms. Since cessation of the trial, we have followed participants for a further 8 years to evaluate

Full Text available with Trip Pro

2006 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology Controlled trial quality: uncertain

13926. Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. (PubMed)

Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. To conduct a phase III trial of adjuvant 13-cis-retinoic acid (13cRA) plus interferon alfa (IFN-alpha) for preventing tumor recurrence and second primary tumors (SPTs) of skin squamous cell carcinoma (SCC) among patients with aggressive skin SCC.Sixty-six patients with aggressive skin SCC were randomly assigned to receive either 6 months of combined 13cRA (1 mg/kg/d (...) required dose reductions for grade 3 or 4 toxicities.Results of this phase III trial do not support 13cRA plus IFN-alpha for adjuvant therapy of aggressive skin SCC. With high rates of tumor recurrence and SPTs, patients with aggressive skin SCC continue to have an unmet medical need, with devastating mortality, morbidity, and financial consequences. Promising agents with preclinical and early clinical results relevant to aggressive skin SCC deserve a high priority for future clinical drug development.

2007 Journal of Clinical Oncology Controlled trial quality: uncertain

13927. Second primary cancers in patients with squamous cell carcinoma of the skin (PubMed)

Second primary cancers in patients with squamous cell carcinoma of the skin The occurrence of second primary cancers was explored in patients with squamous cell cancer of the skin (SCC). The excess incidence subsequent to SCC was mainly in cancers related to sunlight and smoking, and in lymphoproliferative malignancies, it was largest (10-fold) in salivary gland cancer.

Full Text available with Trip Pro

2004 British journal of cancer

13928. Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR

Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Study (...) of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR (CTXSCC) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00240682 Recruitment Status : Completed First Posted : October 18, 2005 Last Update Posted : February 22, 2012 Sponsor: Centre Hospitalier of Chartres Collaborator: Hospital

2005 Clinical Trials

13929. ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin

ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00054691 Recruitment Status : Completed First Posted : February 7, 2003 Results First Posted : February 12, 2015 Last Update Posted : March 13, 2015 Sponsor: M.D. Anderson

2003 Clinical Trials

13930. Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck

Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00519077 Recruitment Status : Completed First Posted : August 21, 2007 Results

2007 Clinical Trials

13931. Cutaneous human papillomaviruses found in sun-exposed skin: Beta-papillomavirus species 2 predominates in squamous cell carcinoma. (PubMed)

Cutaneous human papillomaviruses found in sun-exposed skin: Beta-papillomavirus species 2 predominates in squamous cell carcinoma. A spectrum of cutaneous human papillomaviruses (HPVs) is detectable in nonmelanoma skin cancers, as well as in healthy skin, but the significance that the presence of these types of HPV DNA has for the pathogenesis of skin cancer remains unclear.We studied 349 nonimmunosuppressed patients with skin lesions (82 with squamous cell carcinomas, 126 with basal cell (...) carcinomas, 49 with actinic keratoses, and 92 with benign lesions). After superficial skin had been removed by tape, paired biopsy samples--from the lesion and from healthy skin from the same patient--were tested for HPV DNA. Risk factors for HPV DNA were analyzed in multivariate models.Overall, 12% of healthy skin samples were positive for HPV DNA, compared with 26% of benign lesions, 22% of actinic keratoses, 18% of basal cell carcinomas, and 26% of squamous cell carcinomas. HPV DNA was associated

Full Text available with Trip Pro

2007 Journal of Infectious Diseases

13932. The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma. (PubMed)

The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma. Actinic keratoses (AKs) are intraepidermal skin tumors that have the potential to progress to squamous cell carcinomas (SCCs). SCCs are the second most common cancer with more than 200,000 cases each year in America. Approximately 10% of AKs will progress to SCCs. This progression is thought to be due to chronic sun exposure, specifically ultraviolet B sunlight.Understanding the kinetics

2007 Dermatologic Surgery

13934. Invasive squamous cell carcinoma of the skin: defining a high-risk group. (PubMed)

Invasive squamous cell carcinoma of the skin: defining a high-risk group. Unlike its more common non-invasive form, invasive squamous cell carcinoma (SCC) of the skin can be biologically aggressive and is prone to recur. The objectives of this study were to identify relevant clinicopathologic prognostic factors associated with the outcomes of patients with invasive SCC in order to define a high-risk group.We retrospectively reviewed the records of patients with invasive cutaneous SCC (...) carcinomas (hazard ratio [HR] = 2.92, P = .016), scar carcinomas (HR = 3.12, P = .008), tumor size > 2 cm (HR = 3.79, P = .006), and regional nodal disease (HR = 5.77, P < .0001) as significant risk factors for recurrence or death. On multivariate analysis, however, only regional nodal disease at presentation (HR = 7.64, P < .0001) was found to be significant.Patients with invasive SCCs metastatic to regional nodes constitute a group at high risk for recurrence and death. Such patients should

2006 Annals of Surgical Oncology

13935. Interleukin-10 promoter polymorphisms and susceptibility to skin squamous cell carcinoma after renal transplantation. (PubMed)

Interleukin-10 promoter polymorphisms and susceptibility to skin squamous cell carcinoma after renal transplantation. After organ transplantation, susceptibility to cancer is multifactorial, especially for skin carcinomas. Risk factors may include genetic susceptibilities, such as the control of cytokine production. Interleukin-10 is a cytokine that is implicated in tumorigenesis, and it has been shown that polymorphisms in its gene promoter correlate with differential amounts of production (...) . The aim of this study was to investigate a possible association between interleukin-10 gene promoter polymorphisms and the occurrence of skin carcinomas after renal transplantation. Seventy kidney transplant recipients who developed a squamous cell carcinoma or a basal cell carcinoma were examined for polymorphisms in the interleukin-10 gene promoter using polymerase chain reaction based methods. Single base pair mutations were studied at positions -1082, -819, and -592. These patients were compared

Full Text available with Trip Pro

2003 Journal of Investigative Dermatology

13936. The lysyl oxidase LOX is absent in basal and squamous cell carcinomas and its knockdown induces an invading phenotype in a skin equivalent model. (PubMed)

The lysyl oxidase LOX is absent in basal and squamous cell carcinomas and its knockdown induces an invading phenotype in a skin equivalent model. Lysyl oxidase initiates the enzymatic stage of collagen and elastin cross-linking. Among five isoforms comprising the lysyl oxidase family, LOX is the better studied. LOX is associated to an antitumor activity in ras-transformed fibroblasts, and its expression is down-regulated in many carcinomas. The aim of this work was to shed light on LOX (...) functions within the epidermis by studying its expression in human basal and squamous cell carcinomas and analyzing the effect of its enzymatic activity inhibition and protein absence on human keratinocytes behavior in a skin equivalent. In both carcinomas, LOX expression by epidermal tumor cells was lacking, while it was up-regulated around invading tumor cells in association with the stromal reaction. Lysyl oxidase activity inhibition using beta-aminoproprionitrile in a skin equivalent model prepared

Full Text available with Trip Pro

2006 Clinical Cancer Research

13937. LRIG-1 provides a novel prognostic predictor in squamous cell carcinoma of the skin: immunohistochemical analysis for 38 cases. (PubMed)

LRIG-1 provides a novel prognostic predictor in squamous cell carcinoma of the skin: immunohistochemical analysis for 38 cases. The LRIG-1 gene (formerly LIG-1) encodes a type 1 transmembrane glycoprotein with an extracellular region of 15 leucine-rich repeats and 3 immunoglobulin-like domains. LRIG-1 interacts with ErbB receptors, down-regulating the downstream signals. Because ErbB signaling is disrupted in cutaneous squamous cell carcinoma (SCC), we examined LRIG-1 expression in cutaneous (...) expression intensity of tumor cells with histologic differentiation of SCC. Furthermore, we found a significant inverse correlation with metastatic rate (p = .02). When the overall survival of SCC patients was statistically compared between high and low LRIG-1 expression groups, a significant survival benefit for the patients in the former group was found (p = .03).LRIG-1 expression is an excellent candidate for a prognostic indicator of cutaneous SCC.

2005 Dermatologic Surgery

13938. Artificial skin as a valuable adjunct to surgical treatment of a large squamous cell carcinoma in a patient with epidermolysis bullosa. (PubMed)

Artificial skin as a valuable adjunct to surgical treatment of a large squamous cell carcinoma in a patient with epidermolysis bullosa. Among tissue-engineered skins, two bilayered cellular constructs and one cryopreserved dermal substitute have been approved for the treatment of epidermolysis bullosa. Nevertheless, the application of artificial skin technology to surgical treatment of squamous cell carcinomas in a patient with epidermolysis bullosa has never been reported.To reconstruct (...) the large defect remaining after squamous cell carcinoma excision in a patient with dominantly inherited dystrophic epidermolysis bullosa.To apply a 10 x 15 cm Integra sheet (Integral Life-sciences Corporation, Plainsboro, NJ, USA) (an acellular collagen matrix coated with a thin polysiloxane elastomer) to the excised area and 3 weeks later to cover the Integra sheet with an ultrathin meshed skin graft.The graft take was complete, and the donor site totally regenerated, except for three small bullae

2005 Dermatologic Surgery

13939. Disseminated squamous cell carcinoma of the skin. (PubMed)

Disseminated squamous cell carcinoma of the skin. Squamous cell carcinoma (SCC) accounts for a large proportion of nonmelanoma skin cancers. It may appear mainly on the skin and the mucous membranes; however, it may also appear on any part of the body. The tumor originates from atypical keratinocytes. This tumor, which can be locally destructive, has a metastasis rate of 5% to 10%.To present a patient with disseminated primary SCC of the skin.In this report, we present a unique case (...) original case of disseminated SCC of the skin is presented.

2003 Dermatologic Surgery

13940. Cyclin A and beta-catenin expression in actinic keratosis, Bowen's disease and invasive squamous cell carcinoma of the skin. (PubMed)

Cyclin A and beta-catenin expression in actinic keratosis, Bowen's disease and invasive squamous cell carcinoma of the skin. Actinic keratosis (AK) has been defined as a precancerous lesion or an early phase in the evolution of squamous cell carcinoma (SCC) and histological changes seen in the individual cells of an AK are indistinguishable from those seen in SCC, which invade the dermis. Cyclin A is an increasingly utilized proliferation marker that has functions in both S phase (DNA (...) replication) and initiation of mitosis, whereas alterations of beta-catenin, the molecule involved in cell-cell adhesion and in signalling transduction, could promote invasive and proliferative capacities of malignant tumours.To determine cyclin A and beta-catenin expression pattern in cutaneous SCC and in in situ lesions classified as keratinocytic intraepidermal neoplasia (KIN) and, using traditional terms, as AK and Bowen's disease (BD), and to analyse it in relation to SCC differentiation, diameter

2005 British Journal of Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>